Bayer Shares at a Crossroads: Analyst Targets Stretch from €40.50 to €65 as Legal Calendar Narrows

Bayer stock up 32% YTD, but analyst price targets diverge by €24.50 as Supreme Court ruling impact remains unclear; key court dates in August.

Bayer stock has staged a remarkable rally — up nearly 32% since the start of the year and 43% over the past month — yet the euphoria is far from universal. The gap between the most bullish and most bearish analyst price targets has widened to an extraordinary €24.50, reflecting deep uncertainty about how the company’s legal wins will translate into lasting shareholder value.

The shares closed Friday at €50.18, down 1.03% on the day and 5.39% lower on the week, after touching a 52-week high of €53.86 on 3 July. That high came on the heels of a landmark US Supreme Court ruling in Monsanto v. Durnell, which held that plaintiffs cannot sue Bayer over the absence of a cancer warning on Roundup labels. The decision provided a powerful tailwind, but its practical effect depends heavily on how lower courts apply it.

A Split on the Street

Eighteen analysts covering the stock peg a consensus target of €51.92, barely above the current price, with an average rating of “Outperform.” The extremes tell a different story: the lowest target sits at €40.50, the highest at €65.00.

Goldman Sachs’s James Quigley lifted his target from €55 to €62.50 and kept a Buy rating, arguing for a reduced discount on the pharmaceuticals business and lower estimated cost of capital. Deutsche Bank’s Virginie Boucher-Ferte went further, raising her target from €45 to €60 and upgrading the stock from Hold to Buy. Her reasoning: the glyphosate overhang is fading and investors are refocusing on operations.

Not everyone is convinced. Berenberg’s Sebastian Bray increased his target from €40.50 to €55 — a notable move but still below the consensus. JPMorgan’s Richard Vosser stayed at €50 with an Overweight rating, expecting solid second-quarter numbers on 7 August but no major swing from the report itself.

Two Court Dates, One Stock

The dispute over Roundup liability remains the dominant catalyst. In San Francisco, federal judge Vincent Chhabria is weighing how far the Supreme Court ruling reaches. He postponed a scheduled hearing and told both sides their initial submissions were “unsatisfactory.” Plaintiffs’ attorney Robin Greenwald insists the ruling only covers failure-to-warn claims and does not affect other legal theories. A final decision is still pending.

Separately, a $7.25 billion class settlement covering roughly 60,000 state-court claims requires final approval. Judge Boyer of the Missouri Circuit Court set the hearing for 19 August. Bayer has voiced support for the timeline. If the deal is confirmed, the bulk of the remaining litigation would disappear, clearing the way for a fuller focus on the pharmaceutical and crop-science businesses.

Technical Strains and Debt Pressure

The rally has pushed the stock into overheated territory. The 14-day relative strength index stands at 70.4, a classic overbought signal. The share price trades 24.95% above its 50-day moving average of €40.16 and 33.18% above the 200-day average of €37.68 — gaps that historically rarely persist for long. The 30-day annualized volatility of 61.88% is unusually high for a DAX heavyweight, meaning any negative news could trigger an outsized reaction.

Fundamentals also give cautious analysts ammunition. Bayer carries net financial debt of €32.5 billion. Free cash flow in the first quarter of 2026 fell to minus €2.32 billion, compared with minus €1.53 billion a year earlier. Chief Financial Officer Wolfgang Nickl has guided for total cash outflows of roughly €5 billion for the full year. These figures help explain why not every house shares Deutsche Bank’s optimism.

The Road Ahead

Bayer entered a quiet period on 15 July, limiting public statements until the half-year report on 7 August (some sources mention the 4th, but the company has confirmed the 7th). That earnings release will be the first real test of whether legal progress is translating into operational momentum, especially in cash flow and leverage metrics.

Twelve days later, on 19 August, the Missouri court will decide on the settlement. Until then, the stock remains suspended between a bullish legal story and a set of technical and balance-sheet realities that argue for caution. The wide spread in analyst targets is a direct reflection of how differently the market weights those two forces.